Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness

COPD is a common and lethal chronic condition, recognized as a leading cause of death worldwide. COPD is associated with significant morbidity and disability, particularly among older adults. The disease course is marked by periods of stability and disease exacerbations defined by worsening respirat...

Full description

Saved in:
Bibliographic Details
Published inRespiratory care Vol. 69; no. 6; p. 686
Main Authors Lamberton, Courtney E, Mosher, Christopher L
Format Journal Article
LanguageEnglish
Published United States 01.06.2024
Subjects
Cost-Benefit Analysis
Disease Progression
Dyspnea - etiology
Dyspnea - rehabilitation
Exercise Therapy - economics
Exercise Therapy - methods
Exercise Tolerance
Humans
Patient Education as Topic
Patient Readmission - statistics & numerical data
Pulmonary Disease, Chronic Obstructive - complications
Pulmonary Disease, Chronic Obstructive - economics
Pulmonary Disease, Chronic Obstructive - rehabilitation
Quality of Life
mortality
COPD exacerbation
pulmonary rehabilitation
hospitalization
COPD
Online AccessGet more information

Cover

More Information
Summary:COPD is a common and lethal chronic condition, recognized as a leading cause of death worldwide. COPD is associated with significant morbidity and disability, particularly among older adults. The disease course is marked by periods of stability and disease exacerbations defined by worsening respiratory status resulting in a high burden of health care utilization and an increased risk of mortality. Treatment is focused on pharmacologic therapies, but these are not completely effective. Pulmonary rehabilitation (PR) represents a key medical intervention for patients with chronic respiratory diseases, including COPD. PR provides individualized and progressive exercise training, education, and self-management strategies through a comprehensive and multidisciplinary program. PR has been associated with improvement in exercise capacity, health-related quality of life, and dyspnea in patients living with COPD. Moreover, PR has been associated with improvements in hospital readmission and 1-y survival. In addition to the clinical benefits, PR is estimated to be a cost-effective medical intervention. Despite these benefits, participation in PR remains low. We will review the evidence for PR in each of these benefit domains among patients with stable COPD and in those recovering from a COPD exacerbation.
ISSN:1943-3654
DOI:10.4187/respcare.11541